Investor Presentaiton

Cardiovascular milvexian Camzyos MYK-224 Data from the SSP Phase 2 study gives us confidence to move to Phase 3 in combination with anti-platelet treatments Combination Therapy AXIOMATIC-SSP study¹ Symptomatic ischemic stroke Fatal bleed & Symptomatic intracranial hemorrhage 12 7.7% Incidence rate (%, 95% CI) + a 00 10 ~ 30% RRR versus placebo 5.5% Ph3 SSP Dose 4.6% 3.8% 4.0% 3.5% 0.9% Efficacy Safety 2 0.3% 0.3% Dose 0% 0% 0% 0 Response Placebo 25 mg QD 25 mg BID 50 mg BID 100 mg BID 200 mg BID milvexian Ill Bristol Myers Squibb™ 1. Sharma et al, ESC 2022 Phase 2 data supports Phase 3 studies in SSP and ACS Clinically meaningful (-30%) reduction in ischemic stroke (primary endpoint for Phase 3 SSP) across several fold dose range . • • • • No fatal bleeding No signal for increase in intracranial bleeds No apparent dose response in bleeding Dose response in ischemic stroke with early plateau at 25mg BID Phase 3 dose 25mg BID Not for Product Promotional Use 116

View entire presentation